Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jason Dominguez

Physician Assistant Odessa, TX Physician Assistant

NPI 1861608424 CMS profile 10477631

315 E 5Th St, Odessa, TX 79761

Open in the dashboard

General payments

$15,720

757 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Dominguez of Odessa, TX is reported in the CMS Open Payments database as having received $15,720 across 757 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,682 71
2024 General $2,459 114
2023 General $4,775 244
2022 General $3,825 199
2021 General $2,980 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Dominguez
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jason Dominguez were reported at $1,682. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jason Dominguez Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,980 $132 $37–$438 $132
2022 $3,825 $155 $48–$522 $149
2023 $4,775 $167 $52–$557 $160
2024 $2,459 $178 $55–$600 $164
2025 $1,682 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,895 155 payments
  2. Sun Pharmaceutical Industries Inc. $1,344 62 payments
  3. Regeneron Healthcare Solutions, Inc. $1,156 49 payments
  4. Novartis Pharmaceuticals Corporation $1,123 71 payments
  5. Lilly USA, LLC $1,066 52 payments
  6. Amgen Inc. $1,021 39 payments
  7. E.R. Squibb & Sons, L.L.C. $938 29 payments
  8. UCB, Inc. $891 38 payments
  9. Galderma Laboratories, L.P. $733 18 payments
  10. LEO Pharma Inc. $719 27 payments
  11. Other $3,835 217 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,730 747 payments
  2. Consulting Fee $500 2 payments
  3. Education $490 8 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI $1,572 76 payments
  2. RINVOQ $1,190 73 payments
  3. Otezla $1,021 39 payments
  4. TALTZ $946 49 payments
  5. DUPIXENT Inflammation And Immunology $897 36 payments
  6. ILUMYA $725 27 payments
  7. ADBRY $719 27 payments
  8. SOTYKTU $691 26 payments
  9. DUPIXENT Immunology $615 33 payments
  10. TREMFYA $593 24 payments
  11. Other $7,660 425 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

633

Median for Physician Assistant: 241

Drug cost

$213,194

Median for Physician Assistant: $4,110

Branded share of claims

4.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 16 $109,978
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $90,285
Clobetasol Propionate Generic 83 $3,341
Fluocinonide Generic 53 $2,883
Ketoconazole Generic 88 $1,342
Triamcinolone Acetonide Generic 53 $1,063
Fluorouracil Generic 15 $1,048
Mupirocin Generic 113 $923
Clindamycin Phosphate Generic 15 $549
Mometasone Furoate Generic 19 $371

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$60,545

Of which drugs: $1,133

Medicare patients

402

Average age 73

Services billed

1,661

189 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Diabetes 25%
Ischemic heart disease 23%
Depression 20%
Chronic kidney disease 19%
COPD 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $368
$368 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $276
  • GENZYME CORPORATION $18
$295 — —
SKYRIZI
  • AbbVie, Inc. $195
$195 — —
VTAMA
  • Dermavant Sciences, Inc. $178
$178 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $176
$176 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

757 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record